Immuron Limited Revenue Growth Rates (IMRN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Immuron Limited  (NASDAQ: IMRN)
 

IMRN's Revenue Growth by Quarter and Year

Immuron Limited's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IMRN Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December 6.77
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 6.77

IMRNs Annual Revenue
Immuron Limited's Revenue in the fiscal year 2025 $ 6.77 millions
Immuron Limited's Revenue in the fiscal year 2024 $ 4.34 millions
Immuron Limited's Revenue in the fiscal year 2023 $ 1.48 millions
Immuron Limited's Revenue in the fiscal year 2022 $ 0.00 millions
Immuron Limited's Revenue in the fiscal year 2021 $ 0.15 millions




IMRN Revenue fourth quarter 2024 Y/Y Growth Comment
Immuron Limited achieved in the fourth quarter 2024, above Company average Revenue rise of 55.88% year on year, to $ 6.77 millions.

Looking into fourth quarter 2024 results within Major Pharmaceutical Preparations industry 62 other companies have achieved higher Revenue growth. While Immuron Limited' s Revenue jump of 55.88% ranks overall at the positon no. 305 in the fourth quarter 2024.


IMRN Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December 55.88 % 193.24 % - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   55.88 % 193.24 % - -

Financial Statements
Immuron Limited's fourth quarter 2024 Revenue $ 6.77 millions IMRN's Income Statement
Immuron Limited's fourth quarter 2023 Revenue $ 4.34 millions Quarterly IMRN's Income Statement


IMRN Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   55.88 % 193.24 % - -


Back to IMRN Growth rate Comparisons >> Back to IMRN Growth rate Comparisons >>


Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #63
Healthcare Sector #114
Overall #305

Revenue Y/Y Growth Statistics
High Average Low
192.95 % 14.96 % -100 %
 
Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #63
Healthcare Sector #114
Overall #305
Revenue Y/Y Growth Statistics
High Average Low
192.95 % 14.96 % -100 %
 

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Immuron Limited's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IMRN's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IMRN's IV. Quarter Q/Q Revenue Comment


Immuron Limited's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Jun 30 2021)
Cumulative Revenue 12 Months Ending $ 6.77 $ 4.34 $ 1.48 $ 0.00 $ 0.15
Y / Y Revenue Growth (TTM) 55.99 % 192.95 % - - -94.21 %
Year on Year Revenue Growth Overall Ranking # 81 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 55.99 % 192.95 % - - -94.21 %
Seq. Revenue Growth (TTM) Overall Ranking # 81 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
Assuming the Immuron Limited's fiscal year would have ended in Jun 30 2025, Immuron Limited would have reprted above average annual Revenue growth of 55.99% year on year, of $ 7 millions.
This marks a slow-down of the companys growth trends and from the 192.95% surge in Jun 30 2024.

Within the Healthcare sector 32 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 81.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 19
Healthcare Sector # 33
Overall # 81

Revenue TTM Y/Y Growth Statistics
High Average Low
192.95 %
 37.96 %
-94.21 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 19
Sector # 33
S&P 500 # 81
Cumulative Revenue growth Comment
Assuming the Immuron Limited's fiscal year would have ended in Jun 30 2025, Immuron Limited would have reprted above average annual Revenue growth of 55.99% year on year, of $ 7 millions.
This marks a slow-down of the companys growth trends and from the 192.95% surge in Jun 30 2024.

Within the Healthcare sector 32 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 81.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 19
Healthcare Sector # 33
Overall # 81

Revenue TTM Y/Y Growth Statistics
High Average Low
192.95 %
37.96 %
-94.21 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 19
Sector # 33
S&P 500 # 81




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IMRN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Jun 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2025
Phathom Pharmaceuticals Inc 94.12%$ 94.121 millions
Tenon Medical Inc 92.34%$ 92.338 millions
Caribou Biosciences Inc 89.74%$ 89.745 millions
Argenx Se89.08%$ 89.078 millions
Sangamo Therapeutics Inc 88.43%$ 88.425 millions
Agios Pharmaceuticals Inc 86.09%$ 86.086 millions
Oculis Holding Ag85.72%$ 85.722 millions
Alnylam Pharmaceuticals Inc 84.95%$ 84.945 millions
Day One Biopharmaceuticals Inc 83.92%$ 83.915 millions
Neuronetics Inc 82.17%$ 82.169 millions
Arcutis Biotherapeutics Inc 81.48%$ 81.478 millions
Aclarion Inc 80.59%$ 80.590 millions
X4 Pharmaceuticals Inc79.08%$ 79.079 millions
Intellia Therapeutics Inc 78.79%$ 78.787 millions
Envoy Medical Inc 78.57%$ 78.571 millions
Organogenesis Holdings Inc 78.13%$ 78.126 millions
Tg Therapeutics Inc 78.00%$ 78.004 millions
Eton Pharmaceuticals Inc 77.14%$ 77.140 millions
Trisalus Life Sciences Inc 76.95%$ 76.954 millions
Co diagnostics Inc 76.74%$ 76.743 millions
Ss Innovations International Inc76.54%$ 76.537 millions
Cellectis S a 75.76%$ 75.760 millions
Fennec Pharmaceuticals Inc 73.84%$ 73.842 millions
Travere Therapeutics Inc 73.41%$ 73.410 millions
Inspiremd Inc 69.30%$ 69.299 millions
Viridian Therapeutics Inc 68.06%$ 68.056 millions
Sol gel Technologies Ltd 68.04%$ 68.036 millions
Novavax inc 66.61%$ 66.615 millions
Beyond Air Inc 65.61%$ 65.605 millions
Axsome Therapeutics Inc 65.03%$ 65.030 millions


About Immuron Limited Revenue Growth Rates (IMRN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Immuron Ltd (CIK 1660046).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-26-102838
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Immuron Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.